Myomo (MYO) to Release Earnings on Wednesday

Myomo (NYSEAMERICAN:MYO) is projected to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Myomo to post earnings of ($0.12) per share and revenue of $9.24 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Myomo Price Performance

MYO stock opened at $0.86 on Tuesday. The company has a market capitalization of $33.23 million, a P/E ratio of -2.33 and a beta of 1.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.93 and a current ratio of 3.30. Myomo has a 52-week low of $0.61 and a 52-week high of $4.89. The business has a 50-day simple moving average of $0.74 and a two-hundred day simple moving average of $0.86.

Insider Buying and Selling

In other Myomo news, Director Heather C. Getz bought 70,000 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were purchased at an average price of $0.73 per share, for a total transaction of $51,100.00. Following the purchase, the director directly owned 111,754 shares of the company’s stock, valued at approximately $81,580.42. This represents a 167.65% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas F. Kirk bought 72,000 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was acquired at an average price of $0.71 per share, for a total transaction of $51,120.00. Following the purchase, the director directly owned 553,857 shares in the company, valued at approximately $393,238.47. The trade was a 14.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 162,000 shares of company stock worth $116,220 in the last 90 days. Company insiders own 4.54% of the company’s stock.

Hedge Funds Weigh In On Myomo

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Engineers Gate Manager LP boosted its stake in shares of Myomo by 62.8% in the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after buying an additional 11,614 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Myomo by 93.6% in the 3rd quarter. Bank of America Corp DE now owns 30,412 shares of the company’s stock worth $27,000 after buying an additional 14,705 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Myomo in the 1st quarter worth approximately $75,000. Invesco Ltd. purchased a new position in shares of Myomo in the 2nd quarter worth approximately $37,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Myomo in the 2nd quarter worth approximately $38,000. Hedge funds and other institutional investors own 44.99% of the company’s stock.

Analysts Set New Price Targets

Separately, Craig Hallum reiterated a “buy” rating on shares of Myomo in a research note on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.